LONDON, UK: NetScientific plc announced that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB) commenced an underwritten public offering of shares of its common stock. PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune T-cell activating technology, has commenced an underwritten public offering of shares of its…